Physician-directed product information
Review the catalog, available channels, and product-specific regulatory information.
Albacete MedDev coordinates access and pricing across both supplier channels. Which channel a preparation ships from determines how it is prescribed and where it can ship.
Read this before ordering. Compounded preparations are not FDA-approved drugs. Whether a given substance may lawfully be compounded depends on FDA’s approved-drug and bulks-list frameworks, which change — each catalog entry below carries its current standing, and the legend under the filters explains every chip. Nothing on this page is an offer to sell a specific preparation; availability is confirmed by the supplier at ordering time. Prices are shared with verified practices on request.
Filter by use case, channel or regulatory status — or search by molecule and mechanism. Expand any card for its available preparations.
Active ingredient of an FDA-approved drug; compounding follows the approved-drug pathway (shortage and essentially-a-copy rules apply).
On FDA's interim Category 1 list — nominated with sufficient information; FDA does not intend to act against compounding with it during the interim period. Route or salt-form carve-outs may apply; see the entry note.
Standing differs between the 503A and 503B pathways; confirm with the dispensing pharmacy which pathway your preparation uses.
Nominated without sufficient supporting information; not currently authorized for compounding.
Previously nominated (several were on FDA's 2023 safety-risk list) but the nomination was withdrawn — no active authorization for compounding today.
Not an approved-drug component and not on any FDA bulks list — no pathway currently authorizes compounding with this substance.
FDA has identified significant safety risks on its interim lists (503A and/or 503B); not permitted in compounding.
Transitioned to biologic licensure (2020) and is outside the 503A/503B bulk-compounding framework entirely.
Not a drug substance — ordering supplies carried by the same channels.
Statuses reflect FDA’s 503A/503B bulk-substances framework as verified on the date this page was generated; always confirm current status with the dispensing pharmacy.
GLP-1-class incretin therapies and metabolic peptides anchor modern medical weight-management programs. This group spans the approved-drug substances used in compounded titration protocols alongside investigational metabolic peptides — eligibility differs sharply molecule to molecule, so check each status chip.
Small-molecule NNMT inhibitor that raises intracellular NAD+ and preserves SAM.
Ordered in weight-management and metabolic protocols; studied preclinically for adipocyte metabolism.
Absent from all FDA compounding lists; a Jan 2026 FDA warning letter states it is not eligible for 503B compounding exemptions.
Modified hGH fragment 176-191 studied for lipolysis without growth-receptor activity.
Ordered in fat-metabolism protocols; human weight-loss trials did not meet endpoints.
Placed in 503A Category 2 in 2023, removed after nominator withdrawal in 2024; advisory committee voted against listing (Dec 2024). No active authorization.
Long-acting amylin analog studied with semaglutide (CagriSema) for weight management.
Ordered in adjunct-satiety protocols; still in clinical development.
Investigational; on no FDA compounding list. Covered by FDA's explicit cannot-be-compounded statement for unapproved GLP-1-adjacent peptides.
Triple agonist (GIP/GLP-1/glucagon receptors) in late-stage clinical development.
Ordered in research-adjacent metabolic protocols; not an approved drug anywhere yet.
Investigational; on no FDA compounding list. FDA states it cannot be used in compounding under federal law and has issued warning letters.
GLP-1 receptor agonist slowing gastric emptying and improving satiety and glycemic control.
Active ingredient of approved products (Ozempic, Wegovy, Rybelsus); compounded versions are ordered for individualized dosing/format needs.
Approved-drug substance (Ozempic/Wegovy/Rybelsus). FDA's shortage ended Feb 2025 and copy-compounding flexibilities ended in 2025; compounded semaglutide is limited to genuinely individualized preparations.
Dual GIP/GLP-1 receptor agonist with additive effects on satiety and insulin sensitivity.
Active ingredient of approved products (Mounjaro, Zepbound); compounded versions ordered for individualized dosing/format needs.
Approved-drug substance (Mounjaro/Zepbound). Shortage resolved Dec 2024; compounded copies are constrained — individualized preparations only.
Secretagogues that act on the GHRH receptor or the ghrelin receptor to support endogenous growth-hormone pulsatility, ordered in body-composition, recovery and healthy-aging protocols. Regulatory status varies widely in this group — several molecules have no active FDA bulks-list authorization, so check each chip.
GHRH analog (no-DAC/mod GRF 1-29) extending GH pulse amplitude.
Ordered in GH-axis protocols, usually blended with ipamorelin.
Placed in 503A Category 2 in Sept 2023; nomination since withdrawn — no current 503A or 503B pathway.
GHRH analog + ghrelin-receptor agonist for synergistic GH pulsatility.
The standard GH-axis pairing.
Blend status follows its least-permissive component (IPAMORELIN): Ipamorelin is not a component of any FDA-approved drug; FDA currently lists ipamorelin acetate in Category 2 (significant safety risks) of its 503B interim compounding policy, and its 503A nomination has been withdrawn, so it appears on no list of substances eligible for compounding.
Native growth-hormone-releasing hormone acting on pituitary somatotrophs.
Ordered in GH-axis assessment and support protocols.
No approved product; absent from FDA's bulks lists (distinct from sermorelin and gonadorelin).
Ghrelin-receptor agonist increasing GH pulse with mild appetite effect.
Ordered in GH-axis protocols; older secretagogue generation than ipamorelin.
503A Category 3 (insufficient supporting information); 503B status splits by route (Category 2 injectable/nasal).
Ghrelin-receptor agonist with pronounced appetite stimulation.
Ordered where appetite support is a goal alongside GH-axis effect.
503A Category 3; Category 2 on the 503B interim list.
Long-arginine-3 IGF-1 analog with extended half-life and reduced binding-protein affinity.
Ordered in research-adjacent anabolic protocols.
Different active moiety from approved mecasermin (Increlex); on no FDA compounding list.
Selective ghrelin-receptor agonist (GH secretagogue) with minimal cortisol/prolactin effect.
Ordered in GH-axis and recovery protocols, alone or in blends.
Ipamorelin is not a component of any FDA-approved drug; FDA currently lists ipamorelin acetate in Category 2 (significant safety risks) of its 503B interim compounding policy, and its 503A nomination has been withdrawn, so it appears on no list of substances eligible for compounding.
GHRH 1-29 fragment stimulating endogenous GH release with preserved feedback.
Long compounding history in GH-axis support; formerly approved as Geref.
Geref NDAs were withdrawn in 2009 (not for safety reasons). Sermorelin is absent from the 503A category lists but sits in 503B interim Category 1 as an approved-drug component — confirm which pathway your preparation uses.
Stabilized GHRH analog; reduces visceral adipose tissue in HIV-associated lipodystrophy.
Active ingredient of approved Egrifta; ordered off-label in body-composition protocols.
Active ingredient of marketed EGRIFTA SV / EGRIFTA WR — approved-drug pathway applies.
Tesamorelin + ipamorelin pairing an approved-drug GHRH analog with a secretagogue.
Ordered in body-composition protocols.
Blend status follows its least-permissive component (IPAMORELIN): Ipamorelin is not a component of any FDA-approved drug; FDA currently lists ipamorelin acetate in Category 2 (significant safety risks) of its 503B interim compounding policy, and its 503A nomination has been withdrawn, so it appears on no list of substances eligible for compounding.
Peptide hormones with long clinical histories and approved reference products, ordered for fertility, endocrine and obstetric-adjacent indications under physician direction.
Human chorionic gonadotropin — LH-receptor agonist maintaining testicular function.
Approved products exist (e.g., Pregnyl, Novarel); ordered in fertility and TRT-adjunct protocols.
Approved hCG products transitioned to biologic licenses in March 2020, taking hCG outside the 503A/503B bulk-compounding framework entirely — ask the supplier what they actually dispense.
Posterior-pituitary nonapeptide; uterotonic and social-bonding neuromodulator.
Approved as Pitocin for obstetric use; compounded formats ordered for off-label protocols.
Approved (Pitocin); 503B interim list marks it as an approved-drug component.
The repair-and-recovery group: peptides studied preclinically for angiogenesis, fibroblast activity and tissue remodeling. Most of this group is investigational with limited human data, and several members lack any FDA compounding authorization — review each status before ordering.
Erythropoietin-derived innate-repair-receptor agonist (cibinetide) without erythropoietic effect.
Studied in small human trials for sarcoidosis small-fiber neuropathy; ordered for neuropathic-support protocols.
503A Category 3 — nominated with inadequate supporting information.
Synthetic gastric pentadecapeptide studied preclinically for angiogenesis and tendon/gut repair.
Widely ordered in soft-tissue recovery protocols despite the evidence being almost entirely animal work.
On FDA's 2023 safety-risk list, later moved to nominated-but-withdrawn; no active authorization today. A July 2026 advisory committee vote recommended future listing — non-binding, nothing compoundable yet.
Mechano growth factor — IGF-1 splice variant expressed after mechanical muscle stress.
Ordered in muscle-recovery protocols; evidence is preclinical.
503A Category 3 — nominated without sufficient supporting information; not authorized.
PEGylated MGF extending half-life of the splice-variant peptide.
Ordered in muscle-recovery protocols; evidence is preclinical.
Former 503A Category 2; nomination withdrawn — on no current list.
Thymosin beta-4 fragment involved in actin regulation, cell migration and angiogenesis.
Ordered in recovery protocols, often blended with BPC-157.
Same 2023 cohort as BPC-157, now nominated-but-withdrawn (FDA's entry covers the LKKTETQ fragment); no active authorization.
BPC-157 + TB-500 recovery blend.
Ordered as a combined soft-tissue recovery stack.
Blend status follows its least-permissive component (BPC-157): On FDA's 2023 safety-risk list, later moved to nominated-but-withdrawn; no active authorization today. A July 2026 advisory committee vote recommended future listing — non-binding, nothing compoundable yet.
Mitochondrial, senolytic and cellular-energetics peptides ordered in longevity and healthspan protocols. Evidence ranges from early human trials to purely preclinical work; status chips mark where FDA has weighed in.
AMPK-pathway small molecule ordered in metabolic-endurance protocols.
Capsule format; early-stage evidence.
Not on any FDA compounding list; not an approved drug (small molecule, not a peptide).
Angiotensin IV-derived hexapeptide studied preclinically for HGF/c-Met-linked synaptogenesis.
Ordered in cognitive-support protocols; human evidence absent.
Withdrawn from the 2023 safety-risk list by nominator; FDA noted no human exposure data by any route. No authorization.
Delta sleep-inducing peptide studied for sleep architecture and stress-axis modulation.
Ordered in sleep-quality protocols; human data are old and mixed.
Nominated-but-withdrawn; the July 2026 advisory committee voted against listing DSIP (emideltide).
Synthetic pineal tetrapeptide (AEDG) studied in Russian literature for telomerase activation.
Ordered in longevity protocols; Western clinical evidence absent.
Nominated-but-withdrawn; the July 2026 advisory committee recommended listing (non-binding, no rule yet).
D-retro-inverso FOXO4-p53 interference peptide inducing apoptosis in senescent cells.
Ordered in senolytic protocols; evidence is preclinical.
Never nominated to the bulks lists; no FDA evaluation exists.
Mitochondrial-derived peptide regulating metabolic homeostasis via AMPK.
Ordered in metabolic and exercise-capacity protocols; early human work only.
Nominated-but-withdrawn; July 2026 advisory committee recommended listing (non-binding).
Cardiolipin-binding tetrapeptide (elamipretide) supporting inner-mitochondrial-membrane function.
Studied in mitochondrial disease; ordered in mitochondrial-support protocols.
Approved as FORZINITY (elamipretide, Sept 2025, Barth syndrome). Approved-drug pathway with essentially-a-copy limits.
NAD+ restoration for cellular energetics, ordered as infusions, injections and nasal formats in metabolic-health and recovery protocols.
Nicotinamide adenine dinucleotide — the central redox coenzyme of cellular energy metabolism.
Ordered as injections, infusions and nasal sprays in energy, recovery and healthy-aging protocols.
503A and 503B Category 1 as NAD+. Salt-form caveat: the disodium salt trihydrate sits in Category 3 — confirm the form your pharmacy dispenses.
Copper peptides and melanocortin agonists ordered in aesthetic, hair and skin protocols — from GHK-Cu's collagen-signaling work to melanotan pigmentation peptides that remain investigational.
Copper tripeptide signaling collagen synthesis, angiogenesis and tissue remodeling.
Ordered in skin-quality, hair and wound-adjacent aesthetic protocols; topical and injectable formats.
Category 1 for non-injectable routes only; the injectable nomination was withdrawn April 2026 — confirm route with the pharmacy.
Copper peptide + anti-inflammatory tripeptide blend.
Ordered in skin-calming aesthetic protocols.
Blend status follows its least-permissive component (KPV): Not listed; reviewed by FDA's advisory committee July 2026 for wound healing (advisory only).
GHK-Cu + BPC-157 + TB-500 skin-and-recovery blend.
Ordered in aesthetic-recovery protocols.
Blend status follows its least-permissive component (BPC-157): On FDA's 2023 safety-risk list, later moved to nominated-but-withdrawn; no active authorization today. A July 2026 advisory committee vote recommended future listing — non-binding, nothing compoundable yet.
Linear α-MSH analog (afamelanotide's parent structure) driving eumelanin synthesis.
Ordered in photoprotection-adjacent pigmentation protocols. Afamelanotide implant (Scenesse) is the approved relative.
Afamelanotide (Scenesse implant) is the approved relative; bulk melanotan I has no established compounding authorization.
Cyclic α-MSH analog with pigmentation and libido effects via MC1R/MC4R.
Ordered for pigmentation protocols; carries the most safety caveats in the skin group.
Removed from Category 2 by nominator withdrawal — not a safety clearance; no active authorization.
Neuropeptides from the Russian nootropic literature and sleep-axis peptides, ordered for focus, stress resilience and sleep-quality protocols. Human evidence is limited across this group.
Synthetic tripeptide (EDR) from the Russian peptide-bioregulator literature.
Ordered in cognitive-longevity protocols; evidence is limited to small regional studies.
No listing history in any FDA category; no authorization.
Tuftsin-analog heptapeptide studied in Russian literature for anxiolytic effect without sedation.
Ordered in stress-resilience and focus protocols; nasal and injectable formats.
Removed from Category 2 by nominator withdrawal — not a safety clearance; no active authorization.
Combined anxiolytic + nootropic neuropeptide blend.
Ordered in focus-under-stress protocols.
Blend status follows its least-permissive component (SELANK): Removed from Category 2 by nominator withdrawal — not a safety clearance; no active authorization.
ACTH 4-10 analog studied for BDNF upregulation and cognitive performance.
Ordered in focus and neuro-recovery protocols; nasal and injectable formats.
Not listed; reviewed by FDA's advisory committee July 2026 (advisory only — rulemaking still required).
Thymic peptides, host-defense peptides and anti-inflammatory fragments ordered in immune-support and inflammatory-condition protocols.
α-MSH C-terminal tripeptide with anti-inflammatory signaling at MC1R.
Ordered in gut and skin inflammation protocols; oral, topical and injectable use.
Not listed; reviewed by FDA's advisory committee July 2026 for wound healing (advisory only).
Human cathelicidin host-defense peptide with antimicrobial and immunomodulatory activity.
Ordered in biofilm-adjacent and immune-support protocols; human dosing evidence thin.
Removed from Category 2 by nominator withdrawal — not a safety clearance; no active authorization.
p53-derived membranolytic peptide studied in vitro against cancer cell lines.
Ordered in integrative-oncology-adjacent protocols; no human trials exist.
No listing history; FDA has previously warned on marketing claims for this peptide. Strictly investigational.
Thymalfasin — thymic peptide enhancing T-cell maturation and dendritic function.
Approved in other countries (Zadaxin) and studied broadly; ordered in immune-support protocols.
503B Category 3; not on the 503A category lists. No US-approved product (Zadaxin is ex-US).
Zinc-dependent thymic nonapeptide modulating T-cell differentiation and inflammation.
Ordered in immune-modulation protocols; evidence is preclinical and early human.
503A Category 3 (thymulin acetate); not on the 503B list.
Vasoactive intestinal peptide — broad anti-inflammatory and bronchodilatory neuropeptide.
Ordered in CIRS/mold-illness and pulmonary-support protocols (nasal formats common). Aviptadil is the studied clinical relative.
503A Category 1. Aviptadil has no FDA approval or EUA.
Melanocortin and kisspeptin pathways for sexual-health indications — including the one peptide in this catalog with its own FDA-approved reference product for hypoactive sexual desire disorder.
KISS1R agonist upstream of GnRH; governs the reproductive hormonal axis.
Ordered in fertility-adjacent and libido protocols; human research ongoing.
Still in 503A Category 2 — the one 2023-cohort peptide FDA did not remove. Not permitted in 503A compounding.
Melanocortin-4 agonist (bremelanotide) acting centrally on sexual desire pathways.
Active ingredient of approved Vyleesi (HSDD in premenopausal women); ordered off-label more broadly.
Approved as Vyleesi (bremelanotide) — approved-drug pathway applies.
Non-peptide items carried on the same supplier channels — reconstitution supplies, vitamins and hormone support that practices order alongside peptide protocols.
Bacteriostatic water (0.9% benzyl alcohol) for reconstitution.
Reconstitution of lyophilized peptides.
Supply item.
Master intracellular antioxidant tripeptide (GSH).
Ordered as IV/IM pushes in detox, skin-brightening and recovery protocols.
Category 1 on both the 503A and 503B interim lists.
Injection kits: needles/syringes with alcohol prep pads in sub-Q and IM formats.
Ordered alongside injectable protocols.
Supply items from the 503A channel.
Methylcobalamin — active B12 form for methylation and neurologic support.
Ordered alongside GLP-1 and energy protocols.
Category 1 on both interim lists; a staple co-therapy vitamin.
Testosterone cypionate — long-acting androgen ester.
Approved-drug substance (Depo-Testosterone); ordered in male hormone-optimization programs.
Approved-drug substance (Depo-Testosterone). Schedule III controlled substance; this supplier ships testosterone direct-to-patient only.
No catalog entries match those filters.
Clinic pricing across both channels, volume tiers, and onboarding for portal ordering — shared with verified practices, typically same day.